Phase 3 HERIZON-GEA-01 Analysis Strengthens Survival Evidence for Zanidatamab-Based Regimens in HER2-Positive Gastroesophageal Cancer

• Post author:Austin Newman
• Post published:September 6, 2026
• Post category:Gastroesophageal junction carcinoma

As reported on PharmaBiz, BeOne Medicines has reported positive results from the second interim analysis of the phase 3 HERIZON-GEA-01 trial, further supporting the use of zanidatamab (Ziihera)-containing regimens as…

Continue Reading Phase 3 HERIZON-GEA-01 Analysis Strengthens Survival Evidence for Zanidatamab-Based Regimens in HER2-Positive Gastroesophageal Cancer

TransThera Secures China’s First Approval for Patients With FGFR Inhibitor-Resistant Cholangiocarcinoma

• Post author:Austin Newman
• Post published:August 20, 2026
• Post category:Cholangiocarcinoma

As reported by allsci, China’s National Medical Products Administration (NMPA) has granted conditional approval to TransThera Sciences’ Yochanra (tinengotinib) for adults with unresectable, advanced, or metastatic cholangiocarcinoma (CCA) carrying FGFR2…

Continue Reading TransThera Secures China’s First Approval for Patients With FGFR Inhibitor-Resistant Cholangiocarcinoma

Delcath Begins Phase 2 Study of HEPZATO in Liver-Dominant Metastatic Breast Cancer

• Post author:Austin Newman
• Post published:July 24, 2026
• Post category:Breast Cancer

As reported on Business Wire, Delcath Systems has announced the enrollment and dosing of the first patient in its global Phase 2 DELUMA clinical trial, marking a significant step in…

Continue Reading Delcath Begins Phase 2 Study of HEPZATO in Liver-Dominant Metastatic Breast Cancer

Photo by Wengang Zhai on Unsplash

ASCO GI 2024: Oral Antroquinonol Improved Overall Survival Rates in Metastatic Pancreatic Cancer

• Post author:Jessica Lynn
• Post published:February 2, 2024
• Post category:Pancreatic Cancer

The American Society of Clinical Oncology (ASCO) held its ASCO Gastrointestinal Cancers Symposium from January 18-20, 2024. During the Symposium, doctors, researchers, scientists, and other stakeholders discussed innovative science and…

Continue Reading ASCO GI 2024: Oral Antroquinonol Improved Overall Survival Rates in Metastatic Pancreatic Cancer

source: pixabay.com

These Three Organizations Are Revolutionizing Rare Cancer Research

• Post author:Trudy Horsting
• Post published:February 16, 2022
• Post category:Cancer/Metastatic Melanoma

Rare cancers are a unique research area which necessitate specified attention. Cancer Commons, Pattern.org, and the Rare Cancer Research Foundation are three organizations dedicated to improving the lives of those…

Continue Reading These Three Organizations Are Revolutionizing Rare Cancer Research

source: pixabay.com

Patients with Unresectable Colorectal Liver Metastases and KRAS Mutations Show Reduced Response Rates

• Post author:Rose Duesterwald
• Post published:April 19, 2021
• Post category:Colorectal cancer

  Researchers have been able to identify similarities in outcomes between colorectal liver metastases that cannot be completely removed by surgery (unresectable) and patients with the KRAS mutation. Surgical resection…

Continue Reading Patients with Unresectable Colorectal Liver Metastases and KRAS Mutations Show Reduced Response Rates